Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07581912 | Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases(FALCO) | recruiting | Phase 2 | 40 | Zhejiang UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06758830 | Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. | recruiting | Phase 2 / Phase 3 | 400 | National Cancer Center Affiliate of Vilnius University Hospital Santaros KlinikosOTHER |
| 1 |
| May 11, 2026 |
| clinicaltrials |
| NCT06290505 | A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study(PALEO) | recruiting | Phase 2 | 54 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | May 8, 2026 | clinicaltrials |
| NCT06852820 | 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) | recruiting | Phase 2 | 10 | Melissa LumishOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07448142 | Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer | recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT06205836 | Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer | recruiting | Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06441747 | Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | recruiting | Phase 2 | 40 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT07569679 | Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer | recruiting | Phase 2 | 124 | Air Force Military Medical University, ChinaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07570849 | Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 35 | Shanghai Zhongshan HospitalOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05692024 | COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER(COMMENCER) | recruiting | Phase 1 / Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07014150 | Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma | recruiting | Phase 2 | 33 | Peking Union Medical College HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07122089 | Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis(IOSPHERE) | recruiting | Phase 2 | 80 | Center Eugene MarquisOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07354919 | Axelopran for Advanced Cancer in Patients Receiving Opioids(AxeCan) | recruiting | Phase 2 | 34 | HealthPartners InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07454720 | A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 165 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07503756 | JS212 Combination Therapies in Metastatic Colorectal Cancer | recruiting | Phase 2 | 80 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212(TEADCO) | recruiting | Phase 1 / Phase 2 | 229 | Orion Corporation, Orion PharmaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06050317 | Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer | recruiting | Phase 2 | 25 | Shandong Cancer Hospital and InstituteOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07007182 | Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer | recruiting | Phase 2 | 54 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07030140 | Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma | recruiting | Phase 2 | 38 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07099547 | Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma | recruiting | Phase 2 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07178808 | PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER | recruiting | Phase 2 | 30 | Banner HealthOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07283367 | A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. | recruiting | Phase 1 / Phase 2 | 502 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07560488 | Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07560566 | SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin | recruiting | Phase 2 | 39 | National Taiwan University HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07561060 | Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy(TNTIT) | recruiting | Phase 1 / Phase 2 | 50 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562490 | A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer(CLEAR-04) | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562503 | Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer(CLEAR-03) | recruiting | Phase 2 | 340 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562659 | Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer(CLEAR-01) | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562711 | Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer(CLEAR-02) | recruiting | Phase 2 | 340 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07478523 | FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers(FAPDIG) | recruiting | Phase 2 | 120 | University Hospital, BordeauxOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07559045 | Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 92 | Second Affiliated Hospital of Zunyi Medical UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07559760 | New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer | recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07555678 | Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer:Chase(Chase) | recruiting | Phase 2 | 241 | Fudan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06356584 | Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases | recruiting | Phase 2 | 62 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06385691 | Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer.(MyDIET) | recruiting | Phase 2 | 60 | Centre Leon BerardOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06589830 | TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer | recruiting | Phase 2 | 80 | Suzhou Teligene Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06844422 | Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) | recruiting | Phase 1 / Phase 2 | 37 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06846346 | Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma(GRACIE) | recruiting | Phase 2 | 88 | UNICANCEROTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07274774 | SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma | recruiting | Phase 2 | 184 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05440708 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 193 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06002789 | Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC | recruiting | Phase 2 | 17 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06204094 | Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer(CASINOs) | recruiting | Phase 2 | 37 | Jinhua Central HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07175441 | Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 220 | Riboscience, LLC.INDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07422753 | A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC | recruiting | Phase 2 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer(DUET-GEJ) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06475352 | Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme(FUDOSE) | recruiting | Phase 2 | 400 | UNICANCEROTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06483555 | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel(PANGEA) | recruiting | Phase 1 / Phase 2 | 104 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2026source: clinicaltrials